IVA

Inventiva S.A. American Depositary Receipt (IVA) | Rumor.io

Inventiva

IVA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,299

Bullish sentiment (50-day avg)87%

Price to earnings ratio-1.87

Market capitalization833.9M

Earnings per share-2.16

Dividend yield (TTM)—

Revenue (annual)4.5M

Net income (annual)-354.1M

Social

What share of all stock conversation is about IVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% 0

Oct 29

$IVA's drop may be due to ensuring the company could close a buyout deal at the agreed-upon price.
The company is raising $100 million in capital, which may be contributing to the drop.
Some investors are bullish on $IVA, citing its potential in the MASH/Fibrosis market and its recent price increase.

Generated by AI

Sentiment

Of the messages about IVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +24.14	60.1% -31.59
Bearish	0%	0% 0	0% -24.14	39.9% +31.59

Bullish· Oct 14

Inventiva has secured a significant financing package of up to €348 million, providing a strong foundation for the company's future growth.
$IVA has shown impressive price action, with a spike from 1.89 to 5.40 and potential extension targets of 3.50-4.50 and 4.50+.
The stock has strong buying interest, with a lack of selling pressure and strong bids at $2.20, indicating a potential breakout to higher levels.

Bearish· Oct 7

$IVA's recent price action is suspicious, with 1000x normal volumes on Nasdaq, indicating potential manipulation by a prop desk.
The stock's sudden decline is likely due to a coordinated short-selling effort, with some users predicting a 70% loss of investment in 2 weeks.
$IVA's price volatility is expected to continue, with some users warning of a potential "pull $HKD type of move" and others predicting a significant decline in value.

Generated by AI

Topics

Of the messages about IVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	7.41%	42.61%	59.42%
Analysts	66.67%	50.62%	37.5%	29.65%
Macro	0%	40.74%	18.75%	4.15%
Technical Analysis	33.33%	1.23%	1.14%	6.16%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.63%

May 13

Inventiva's lanifibranor demonstrated improvement in markers of cardiometabolic health in patients with MASH/NASH in the NATIVE Phase IIb clinical trial.
The additional results from the trial were published in Nature Communications, highlighting the potential benefits of lanifibranor.
The NATIVE Phase IIb clinical trial showed that lanifibranor improved markers of cardiometabolic health in patients with MASH/NASH.

Generated by AI

Community

Of the messages about IVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	39.02%	64.2%	70.58%
Newcomers	33.33%	60.98%	35.8%	29.42%

Oct 14

The removal of a significant overhang on Inventiva's stock has been completed, following a $410M financing, which is expected to support the company's efforts to complete a pivotal program and potentially launch its drug commercially.
The financing is seen as a major milestone for Inventiva, and it may alleviate concerns about the company's ability to fund its development plans.
Inventiva's stock is currently showing strong bid activity, with a lack of selling pressure and a significant number of buy orders at a specific price point, which may indicate a potential market movement or increased investor interest.

Generated by AI

News

Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Vail Resorts

U.S. futures mixed as Vail Resorts fell after a Q4 loss miss despite beating sales estimates; several stocks also declined premarket.

23h agobenzinga.com

Truist reiterates Buy on Inventiva stock ahead of phase 3 data

1d agoInvesting.com

Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ...

1d agoYahoo Finance

Inventiva Q2 Earnings Call Highlights

Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study’s 72-week visit earlier this month. Chie

1d agoYahoo Finance

Earnings call transcript: Inventiva tops Q2 2026 estimates as investors stay cautious By Investing.com

1d agoInvesting.com

Inventiva H1 2026 Earnings Call: Complete Transcript - Inventiva (NASDAQ:IVA)

On Monday, Inventiva (NASDAQ:IVA) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and

1d agoBenzinga

Also Discussed

Investors talking about IVA also mention

#	Name	Attention
1	Galapagos NV American Depositary ReceiptGLPG	0%0
2	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
3	ETNB - 89bio, Inc.	——
4	Innate Pharma S.A. Sponsored ADRIPHA	0%0
5	DBV Technologies S.A. Sponsored ADRDBVT	0%0
6	Abivax SAABVX	0.01%-0.01
7	LVTX - LAVA Therapeutics N.V.	——
8	PSTX - Poseida Therapeutics, Inc.	——
9	Edoc Acquisition Corp.ADOC	0%0
10	GNFT - Genfit S.A.	——

Inventiva S.A. American Depositary Receipt

Healthcare
Biotechnology

Inventiva S.A. American Depositary Receipt represents Inventiva S.A., a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical need. The company’s current research and development activities center on treatments for metabolic, fibrotic, inflammatory, and rare diseases, with a pipeline that includes programs in liver disease, oncology, fibrosis, and mucopolysaccharidoses. Inventiva S.A. operates as a biotechnology company with international clinical development activity, combining in-house discovery capabilities with late-stage and earlier-stage therapeutic programs. As an American Depositary Receipt, it provides U.S. market access to the company’s ordinary shares and reflects its role as a cross-border biotech issuer with exposure to specialty drug development and clinical research.

Website

Location

50 rue de Dijon

Daix, 21121

France

Social

What share of all stock conversation is about IVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% 0

Oct 29

$IVA's drop may be due to ensuring the company could close a buyout deal at the agreed-upon price.
The company is raising $100 million in capital, which may be contributing to the drop.
Some investors are bullish on $IVA, citing its potential in the MASH/Fibrosis market and its recent price increase.

Generated by AI

Sentiment

Of the messages about IVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +24.14	60.1% -31.59
Bearish	0%	0% 0	0% -24.14	39.9% +31.59

Bullish· Oct 14

Inventiva has secured a significant financing package of up to €348 million, providing a strong foundation for the company's future growth.
$IVA has shown impressive price action, with a spike from 1.89 to 5.40 and potential extension targets of 3.50-4.50 and 4.50+.
The stock has strong buying interest, with a lack of selling pressure and strong bids at $2.20, indicating a potential breakout to higher levels.

Bearish· Oct 7

$IVA's recent price action is suspicious, with 1000x normal volumes on Nasdaq, indicating potential manipulation by a prop desk.
The stock's sudden decline is likely due to a coordinated short-selling effort, with some users predicting a 70% loss of investment in 2 weeks.
$IVA's price volatility is expected to continue, with some users warning of a potential "pull $HKD type of move" and others predicting a significant decline in value.

Generated by AI

Topics

Of the messages about IVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	7.41%	42.61%	59.42%
Analysts	66.67%	50.62%	37.5%	29.65%
Macro	0%	40.74%	18.75%	4.15%
Technical Analysis	33.33%	1.23%	1.14%	6.16%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.63%

May 13

Inventiva's lanifibranor demonstrated improvement in markers of cardiometabolic health in patients with MASH/NASH in the NATIVE Phase IIb clinical trial.
The additional results from the trial were published in Nature Communications, highlighting the potential benefits of lanifibranor.
The NATIVE Phase IIb clinical trial showed that lanifibranor improved markers of cardiometabolic health in patients with MASH/NASH.

Generated by AI

Community

Of the messages about IVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	39.02%	64.2%	70.58%
Newcomers	33.33%	60.98%	35.8%	29.42%

Oct 14

The removal of a significant overhang on Inventiva's stock has been completed, following a $410M financing, which is expected to support the company's efforts to complete a pivotal program and potentially launch its drug commercially.
The financing is seen as a major milestone for Inventiva, and it may alleviate concerns about the company's ability to fund its development plans.
Inventiva's stock is currently showing strong bid activity, with a lack of selling pressure and a significant number of buy orders at a specific price point, which may indicate a potential market movement or increased investor interest.

Generated by AI

Inventiva

Social

Oct 29

Bullish· Oct 14

Bearish· Oct 7

May 13

Oct 14

Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Vail Resorts

Truist reiterates Buy on Inventiva stock ahead of phase 3 data

Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ...

Inventiva Q2 Earnings Call Highlights

Earnings call transcript: Inventiva tops Q2 2026 estimates as investors stay cautious By Investing.com

Inventiva H1 2026 Earnings Call: Complete Transcript - Inventiva (NASDAQ:IVA)

Also Discussed

Inventiva S.A. American Depositary Receipt

Company Information

Location

Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Vail Resorts

Truist reiterates Buy on Inventiva stock ahead of phase 3 data

Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ...

Inventiva Q2 Earnings Call Highlights

Earnings call transcript: Inventiva tops Q2 2026 estimates as investors stay cautious By Investing.com

Inventiva H1 2026 Earnings Call: Complete Transcript - Inventiva (NASDAQ:IVA)

Also Discussed

Social

Oct 29

Bullish· Oct 14

Bearish· Oct 7

May 13

Oct 14